SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ian@SI who wrote (2319)2/20/2005 12:47:33 PM
From: Ian@SI  Read Replies (1) of 3044
 
Part 4:

VELCADE in combination with prednisone in patients with advanced androgen independent prostate cancer

A phase II study of VELCADE, led by Michael Morris M.D. and Howard I.
Scher, M.D. at Memorial Sloan-Kettering, New York, NY enrolled 30 patients and
examined the efficacy of VELCADE in patients with progressive androgen
independent metastatic prostate cancer. Patients were treated in two groups,
the first 12 patients receiving VELCADE 1.5mg/m2 twice weekly for two out of
three weeks at induction with daily prednisone 10mg, and the next 18 patients
receiving VELCADE 1.3mg/m2 on the same schedule at induction with prednisone
10mg upon progression. All patients received VELCADE 1.6 mg/m2 weekly as
maintenance. Antitumor activity was evaluated based on imaging and measurement
of PSA decline at six and twelve weeks. Investigators reported the following
results from pooled cohorts:

* Of nine patients with measurable disease, two patients achieved stable
PSA and stable scans at 12 weeks;

* Two patients had a stable PSA at 12 weeks but progressed
radiographically;

* One patient in the higher dose group demonstrated a partial response on
scans but PSA continued to rise; and

* Side effects included hematologic, metabolic and hepatic side effects,
neuropathy, syncope, diarrhea and fatigue.
[SNIP]
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News